Exagen (XGN) 10% Owner Jorey Chernett Buys $104K of Stock

Exagen Inc. 10% owner Jorey Chernett purchased 14,000 shares of the company on October 19, 2026. The stock was bought at a price of $7.46 per share, coming to a total value of $104,440, as shown in a Form 4 filing with the Securities and Exchange Commission.

XGN Exagen Inc.

$7.43 ▲ +23.01% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Jorey Chernett's Exagen Trade

The purchase boosted Chernett's direct holdings by a 0.54% margin, lifting the total stake to 2,618,540 shares. The transaction took place on a day when Exagen closed at $7.43.

Other Institutional Activity in Exagen

Other major funds adjusted their positions in Exagen ahead of the period. Wexford Capital LP held steady with 792,855 shares worth about $5.9 million. Nano Cap New Millennium Growth Fund L P grew its holdings by 89,977 shares, ending with 675,000 shares worth about $5.0 million. FourWorld Capital Management, LLC added 156,578 shares for a 35.6% increase, finishing with 596,528 shares valued at about $4.4 million. Silvercrest Asset Management Group, LLC trimmed its stake by 23,129 shares or 4.3% to 514,761 shares worth about $3.8 million, while Kennedy Capital Management, LLC cut its holding by 8,589 shares or 1.7% to 485,048 shares valued at about $3.6 million.

Exagen Inc. Stock Down 3.8%

Shares recently traded around $7.43 as of October 20, 2026, sitting about 39.2% below the 52-week high of $12.23 and well above the 52-week low of $2.59. The company has a market capitalization of roughly $180.0 million and carries a beta of 2.12.

Recent Earnings

Exagen reported trailing-twelve-month revenue of $71.1 million alongside an earnings per share loss of $0.81. The diagnostic test maker posted a negative net margin of 26.6% and a return on equity of -113.8%, with year-over-year revenue growth reaching 15.9%. The next financial report is scheduled for release on November 10, 2026.

Insider Buying and Selling at Exagen Inc.

Insider activity at Exagen included multiple transactions earlier in the year. In June 2026, insiders Chas Mckhann, Scott Kahn, and Frank Stokes each acquired 37,500 shares. More recently, President and CEO John Aballi sold 34,294 shares on October 16, 2026, at an average price of $7.87, reducing his holding by about 4.1% to 805,540 shares.

Analysts Set New Price Targets

Wall Street firms have remained largely positive on the stock. Canaccord Genuity maintained a buy rating on October 19, 2026, with an 11.00 dollar price target, following prior updates from TD Cowen, B. Riley Securities, and BTIG over the prior months. The stock currently carries a consensus strong buy recommendation with a mean price target of $10.57 across seven analyst opinions.

About Exagen

Exagen is a healthcare company based in Vista, California, that develops and sells specialized testing products under the AVISE brand. The firm focuses on tools to help doctors diagnose and monitor complex rheumatic and autoimmune conditions, including rheumatoid arthritis and lupus.

Bottom Line

Investors will look toward the upcoming earnings release on November 10, 2026, for further details on top-line growth and financial progress. Regulatory filings will continue to track whether major owners expand or trim their positions further.